- Previous Close
0.00 - Open
14.00 - Bid 13.40 x 40000
- Ask 14.44 x 40000
- Day's Range
14.00 - 14.00 - 52 Week Range
5.82 - 15.40 - Volume
450 - Avg. Volume
4,163 - Market Cap (intraday)
4.721B - Beta (5Y Monthly) 2.40
- PE Ratio (TTM)
134.00 - EPS (TTM)
0.10 - Earnings Date Aug 22, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals for cancer and rare diseases in Australia, Belgium, Japan, Switzerland, and the United States. The company offers Illuccix for the treatment of prostate cancer; and TLX66-CDx for the treatment of imaging osteomyelitis. Its products candidates include TLX591, a radio antibody-drug conjugate for the treatment of prostate cancer; TLX250-CDx for the treatment and diagnosis of renal (kidney) cancer; TLX101-CDx for brain (glioma) cancer; TLX66-CDx to treat bone marrow conditioning; TLX300-CDx for the treatment and diagnosis of soft tissue sarcoma; and TLX250 for the treatment of clear cell renal cell carcinoma. The company also develops TLX101 for the treatment of glioblastoma (brain cancer); TLX66 for the treatment of bone marrow conditioning; TLX300 for the treatment of soft tissue sarcoma; and TLX592, a prostate cancer therapy candidate for targeted alpha therapy. Telix Pharmaceuticals Limited was founded in 2015 and is headquartered in North Melbourne, Australia.
telixpharma.comRecent News: TLPPF
View More
Performance Overview: TLPPF
Trailing total returns as of 11/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: TLPPF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: TLPPF
View MoreValuation Measures
Market Cap
4.72B
Enterprise Value
4.66B
Trailing P/E
137.11
Forward P/E
58.82
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.55
Price/Book (mrq)
16.89
Enterprise Value/Revenue
11.12
Enterprise Value/EBITDA
97.06
Financial Highlights
Profitability and Income Statement
Profit Margin
7.62%
Return on Assets (ttm)
7.97%
Return on Equity (ttm)
20.49%
Revenue (ttm)
645.68M
Net Income Avi to Common (ttm)
49.19M
Diluted EPS (ttm)
0.10
Balance Sheet and Cash Flow
Total Cash (mrq)
118.84M
Total Debt/Equity (mrq)
5.48%
Levered Free Cash Flow (ttm)
105.93M
Company Insights: TLPPF
TLPPF does not have Company Insights